Good information, and to stress something: the shape of the study if it is "accelerated" is vital. Celsion looked like they had the slam dunk and the shape of the study horked them big time. Basing on other comments it seems we won't have that problem here but it will be something important to watch and understand as we get closer to that timeframe, provided Cellceutix is ready for it. Just passing along one of my lessons learned from that stock.
Bottom line: the acceleration timeframe is a double edged sword.